Karo Bio of Stockholm

BT Catalyst, April, 2000

> Karo Bio of Stockholm, Sweden, has announced that it intends to acquire Novalon Pharmaceutical Corp. of Durham through a noncash issue. If Karo shareholders approve the acquisition later this month, the company stands to gain a leading position in the field of nuclear receptors. Karo plans to keep the Durham operation intact, and Novalon shareholders will hold 20 percent of Karo Bio after the acquisition.

COPYRIGHT 2000 North Carolina Biotechnology Center
COPYRIGHT 2008 Gale, Cengage Learning

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
CXO UnpluggedSmart Business interviews on BNET

See and hear how senior level executives across the Asia Pacific are developing smart business ideas across a variety of sectors. The focus is on the future, and on how businesses need to evolve.

advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement

Content provided in partnership with Thompson Gale